Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Int J Environ Res Public Health. 2021 Sep 4;18(17):9345. doi: 10.3390/ijerph18179345.
Interferon (IFN)-γ-inducible chemokines in the CXCR3/ligand axis are involved in cell-mediated immunity and play a significant role in the progression of cancer. We enrolled patients with lung cancer ( = 144) and healthy volunteers as the controls ( = 140). Initial blood samples were collected and concentrations of IFN-γ and IFN-γ-inducible chemokines CXCL9, CXCL10, and CXCL11 were measured using enzyme-linked immunosorbent assay. Of patients with lung cancer, 125 had non-small cell lung cancer (NSCLC) and 19 had small cell lung cancer. The area under the curve (AUC) (95% CI) of CXCL9 was 0.83 (0.80-0.89) for differentiating lung cancer patients from controls. The levels of all the markers were significantly higher in NSCLC patients with stage IV than in those with stages I-III. A Kaplan-Meier survival analysis showed that NSCLC cancer patients with higher levels of all markers showed poorer survival than those with lower levels. In Cox multivariate analysis of patients with NSCLC, independent prognostic factors for overall survival were CXCL9 and CXCL11. CXCL9 was the only independent prognostic factor for cancer-specific survival. Serum IFN-γ-inducible chemokines may be useful as clinical markers of metastasis and prognosis in NSCLC, and CXCL9 levels showed the most significant results.
干扰素 (IFN)-γ 诱导的趋化因子在 CXCR3/配体轴中参与细胞介导的免疫反应，并在癌症的进展中发挥重要作用。我们招募了肺癌患者（=144）和健康志愿者作为对照组（=140）。采集初始血液样本，并使用酶联免疫吸附试验测量 IFN-γ 和 IFN-γ 诱导的趋化因子 CXCL9、CXCL10 和 CXCL11 的浓度。在肺癌患者中，125 例为非小细胞肺癌（NSCLC），19 例为小细胞肺癌。CXCL9 区分肺癌患者和对照组的曲线下面积（AUC）（95%CI）为 0.83（0.80-0.89）。所有标志物的水平在 IV 期 NSCLC 患者中明显高于 I-III 期患者。Kaplan-Meier 生存分析显示，所有标志物水平较高的 NSCLC 癌症患者的生存情况较水平较低的患者差。在 NSCLC 患者的 Cox 多变量分析中，总生存的独立预后因素是 CXCL9 和 CXCL11。CXCL9 是癌症特异性生存的唯一独立预后因素。血清 IFN-γ 诱导的趋化因子可作为 NSCLC 转移和预后的临床标志物，且 CXCL9 水平显示出最显著的结果。
